glp 1 approved for cardiovascular disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including and neurodegenerative disorders GLP 1 Receptor Agonist Cardiovascular

More specifically, receptors levels in the frontal and temporal cortex were reduced by approximately 50% of control values in AD patients while a 40% reduction was reported in the hippocampus and no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus

Why Does GLP-1 Medication Cause Constipation

The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person

Cellular longevity slowing processes of aging and cellular senescence

Here in the States, Wegovy manufacturer Novo Nordisk has filed for FDA approval of its injection to 7.2 mg and been approved as of March 19, 2026

, , Current Obesity Reports(IF: 11) .